Treatment of Invasive Candida Infections in the Neonatal Intensive Care Unit
- 171 Downloads
Invasive Candida infections are a leading cause of morbidity and mortality in the neonatal intensive care unit (NICU). Extremely preterm and very low birth weight infants are at the highest risk of infection. There are currently no antifungal agents that have FDA-labeling for the treatment of invasive candidiasis in the neonatal population. Based on the current IDSA guidelines, amphotericin and fluconazole are considered first-line options for neonatal candidiasis. The newer antifungal agents (i.e., echinocandins and voriconazole) are currently considered second-line or salvage therapy; however, evidence supporting their use is emerging. This review focuses on the supporting evidence for the selection of antifungal agents for treatment of invasive Candida infections in the NICU.
KeywordsCandida Neonate Infant Antifungal
Conflict of Interest
Megan G. Andrews declares that she has no conflict of interest.
Roshni Patel declares that she has no conflict of interest.
Jamie Miller declares that she has no conflict of interest.
No financial support was provided for this study
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.•• Chitnis AS, Magill SS, Edwards JR, et al. Trends in Candida central line-associated bloodstream infections among NICUs, 1999–2009. Pediatr. 2012;130:e46–52. This study provides the most current trends of Candida spp. bloodstream infections in US NICU’s from 1999–2009. The authors report a decline in the incidence of Candida infections among NICU patients. C. albicans and C. parapsilosis were the most common species identified.CrossRefGoogle Scholar
- 3.Taketomo CK, Hodding JH, Kraus DM. Pediatric dosage handbook. 19th ed. Hudson: Lexi-Comp, Inc; 2012.Google Scholar
- 4.Turkova A, Roilides E, Sharland M. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy – is there a ‘right’ choice? Curr Opin Infect Dis 2011;24:163–71.Google Scholar
- 6.•• Pappas PG, Kauffman CA, Benjamin DK, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35. These guidelines established by the Infectious Diseases Society of America are the most current guidelines addressing the management of invasive candidiasis in several patient populations. There is a section devoted specifically to the treatment of neonatal candidiasis.PubMedCrossRefGoogle Scholar
- 14.•• Ascher SB, Smith PB, Watt K, et al. Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J. 2012;31:439–43. This recent retrospective, database review was the first to report an increased mortality rate in neonates treated with liposomal amphotericin formulations versus amphotericin dexoycholate or fluconazole.PubMedCrossRefGoogle Scholar
- 20.Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed December 2012.Google Scholar
- 33.Kohli V, Taneja V, Sachdev P, Joshi R. Voriconazole in newborns. Ind Pediatr. 2008;45:236–8.Google Scholar
- 34.• Saez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother. 2009;53(3):869–75. This is the first prospective PK study of caspofungin in neonates and infants. Caspofungin dosed at 25 mg/m2 in infants provides a similar plasma exposure to that of adults receiving 50 mg/day. Slight elevations in trough concentrations were noted in neonates and infants, compared to the adult population.PubMedCrossRefGoogle Scholar
- 42.• Mohamed WA, Ismail M. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants. J Trop Pediatr. 2012;58(1):25–30. This study randomized, double-blind trial to compare use of caspofungin and amphotericin B in neonates with invasive candidiasis. Caspofungin treated patients had a statistically significant increase in efficacy rate and lower incidence of adverse effects. Based on their results, the authors propose that caspofungin is an appropriate alternative to amphotericin for the treatment of invasive candidiasis in neonates.PubMedCrossRefGoogle Scholar
- 46.• Hope WW, Smith B, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother. 2010;54:2633–7. This study is the largest micafungin PK study in neonates. The authors combined the data from three smaller PK studies with doses ranging from 0.75–15 mg/kg. Monte Carlo simulations were performed and the authors recommend dosing micafungin at 10 mg/kg/day to achieve adequate CNS concentrations in neonates.PubMedCrossRefGoogle Scholar
- 51.• Cohen-Wolkowiez M, Benjamin Jr DK, Piper L, et al. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmcol Ther. 2011;89:702–7. This is the first PK study of anidulafungin in infants and neonates. This study demonstrated that anidulafungin doses of 1.5 mg/kg/day achieved a similar area under the curve to children receiving the same dose.CrossRefGoogle Scholar
- 56.Zenker PN, Rosenberg EM, Van Dyke RB, et al. Successful medical treatment of presumed Candida endocarditis in critically ill infants. J Pediatr. 1991;119:72–7.Google Scholar